Ali ZH. Cytotoxicity of Miltefosine Against Leishmania Major Promastigotes. Adv Biores 2012; 3 (4): 90-94.
Alonso L and Alonso A. Hemolytic Potential of Miltefosine is Dependent on Cell Concentration: Implications for In Vitro Cell Cytotoxicity Assays and Pharmacokinetic Data. Biochim Biophys Acta Biomembr 2016; 1858: 1160-1164.
Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis Worldwide and Global Estimates of its Incidence. PloS One 2012; 7: 35671.
Bernkop-Schnürch A, Weithaler A, Albrecht K, Greimel A. Thiomers: Preparation and In Vitro Evaluation of A Mucoadhesive Nanoparticulate Drug Delivery System. Int J Pharm 2006; 317 (1): 76-81.
Calvo P, Remuñán-López C, Vila-Jato JL, Alonso M. Novel Hydrophilic Chitosan-Polyethylene Oxide Nanoparticles as Protein Carriers. J Appl Polym Sci. 1997; 63: 125-132.
Chávez-Fumagalli MA, Ribeiro TG, Castilho RO, Fernandes SOA., Cardoso VN, Coelho CSP, et al. New Delivery Systems for Amphotericin B Applied to the Improvement of Leishmaniasis Treatment. Rev Soc Bras Med Trop 2015; 48 (3): 235-242.
Chen M, Wang S, Tan M, Wang Y. Applications of Nanoparticles in Herbal Medicine: Zedoary Turmeric Oil and Its Active Compound β-elemene. Am J Chin Med 2011; 39 (6): 1093-1102.
Chrusciak-Talhari A, Dietze R, Talhari CC, Da-Silva RM, Yamashita EPG, De-Oliveira PG, et al. Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) Guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84 (2): 255-260.
Desjeuxp. Leishmaniasis: Current Situation and New Perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305–318.
DeSouza MC, De-Assis EA, Gomes RS, Marques-Da SEA, Melo MN, Fietto JLR, et al. The Influence of Ecto-Nucleotidases on leishmaniaamazonensis Infection and Immune Response in C57b/6 Mice. Acta Trop 2010; 115: 262–269.
Dorlo TP, Eggelte TA, De-Vries PJ, Beijnen JH. Characterization and Identification of Suspected Counterfeit Miltefosine Capsules. Analyst 2012; 137 (5): 1265-1274.
Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M. Development of a Modified MTT Assay for Screening Antimonial Resistant Field Isolates of Indian Visceral Leishmaniasis. Parasitol Int 2005; 54 (2): 119-122.
Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2012; 2:11-9.
Gkolfinopoulou K, Bitsolas, N, Patrinos S, Veneti L, Marka A, Dougas G et al. Epidemiology of Human Leishmaniasis in Greece, 1981-2011. Euro Surveill 2013; 18 (29): 20532.
Hafdani FN and Sadeghinia N. A Review on Application of Chitosan as a Natural Antimicrobial. World Acad Sci Eng Technol 2011; 50: 252-256.
Kevric I, Cappel MA, Keeling JH. New World and Old World Leishmania Infections: A Practical Review. Dermatol Clin 2015; 33: 579-593.
Khademvatan S, Gharavi MJ, Rahim F, Saki J. Miltefosine-Induced Apoptotic Cell Death On Leishmania Major And L. Tropica Strains. Korean J Parasitol 2011; 49 (1): 17-23.
Kheirandish F, Sharafi AC, Kazemi B, Mohebali M, Sarlak A, Tarahi MJ, et al. Identification of Leishmania Species using PCR Assay on Giemsa-Stained Slides Prepared From Cutaneous Leishmaniasis Patients. Iran J Parasitol 2013; 8: 382.
Launois p, Tacchini CF, Kienym P. Cutaneous Leishmaniasis: Progress Towards a Vaccine. Expert Rev Vaccines 2008; 7: 1277–12871650-1662.
Lima DDS, Gullon B, Cardelle-Cobas A, Brito LM, Rodrigues KA, Quelemes PV, et al. Chitosan-Based Silver Nanoparticles: A Study of the Antibacterial, Antileishmanial and Cytotoxic Effects. J Bioact Compat Polym 2017; 32: 397-410.
Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-Based Nanoparticles as Drug Delivery Systems. Adv Drug Deliv Rev 2008; 60 (15): 1650-1662.
Makhlof A, Werle M, Tozuka Y, Takeuchi H. Nanoparticles of Glycol Chitosan and its Thiolated Derivative Significantly Improved the Pulmonary Delivery of Calcitonin. Int J Pharm 2010; 397: 92-95.
Mcgwire B & Satoskar A. Leishmaniasis: Clinical Syndromes and Treatment. Qjm 2013; 107: 7-14.
Minodier P and Parola P. Cutaneous Leishmaniasis Treatment. Travel Med Infect Dis 2007; 5: 150–18.
Murray HW, Berman JD, Davies CR, Saravia NG. Advances in Leishmaniasis. Lancet 2005; 366: 1561–1577.
Ribeiro JB.P, Miranda-Vilela AL, Graziani D, De-Aguiar GMR, Amorim AAS, Garcia RD, et al. Evaluation of the Efficacy of Systemic Miltefosine Associated with Photodynamic Therapy With Liposomal Chloroaluminium Phthalocyanine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (L.) Amazonensis in C57bl/6 Mice. Photodiagnosis Photodyn Ther 2016; 13: 282-290.
Singh N, Kumar M, Singh RK. Leishmaniasis: Current Status of Available Drugs and New Potential Drug Targets. Asian Pac J Trop Med 2012; 5 (6): 485–497.
Soong L, Henard, CA, Melby PC. Immunopathogenesis of Non-Healing American Cutaneous Leishmaniasis and Progressive Visceral Leishmaniasis. Semin Immunopathol 2012; 34 (6): 735-751.
Tiuman TS, Santos AO, Ueda-Nakamura T, Dias-Filho BP, Nakamura CV. Recent Advances an Leishmaniasis Treatment. Int J Infect Dis 2011, 15 (8), 525-532.
Tiyaboonchai W. Chitosan Nanoparticles: A Promising System for Drug Delivery. Nare Uni J 2003; 11 (3): 51-66.
Varela-M RE, Villa-Pulgarin JA, Yepes E, Müller I, Modolell M, Muñoz DL, et al. In Vitro and In Vivo Efficacy ff Ether Lipid Edelfosine against Leishmania Spp. And SbV-Resistant Parasites. PLoS Negl Trop Dis 2012; 6 (4): 1612.
Yasinzai M, Khan M, Akhtar N, Shahnaz G. Drug Resistance in Leishmaniasis: Current Drug –Delivery Systems and Future Perspectives. Future Med Chem 2013; 5 (15): 1877-1888.